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INTRODUCTION
Tight junctions are located at the extreme apical region of 
junction-associated complexes in epithelial and endothelial 
cells, where they play important roles maintaining cell polari-
ty, cell adherence and regulating cell proliferation and differ-
entiation [1,2]. Tight junctions are composed of the junctional 
adhesion molecules, claudins (CLDNs) and occludins [3-5]. 
CLDNs are major components of tight junctions, forming the 
backbone of the tight junction strands [2]. CLDNs expression 
has been reportedly altered in several cancers [6,7]. Whether 
upregulated or downregulated, the structure and functions of 
tight junctions are often abnormal in a number of cancers [8]. 
Tight junction dysfunction has been presumed as a mech-   
anism for the loss of cell adhesion, and an important step for 
the progression of cancer to metastasis. The expression and 
functions of CLDNs may be highly tissue- and cell-specific, as 
CLDNs may be useful molecular markers for many different 
cancers because of their highly specific expression patterns 
[7,9]. CLDN proteins may also be promising targets for anti-
body-based therapy because they are transmembrane proteins 
with two relatively large extracellular loops [10]. 
CLDN6 is a member of the CLDN family and plays impor-
tant roles maintaining the permeability barrier and transepi-
thelial resistance of epidermal cells [11]. In our previous work, 
we found that CLDN6 expression was downregulated in hu-
man and rat mammary cancer cell lines [12]. Furthermore, 
MCF-7 cells transfected with CLDN6 grew slowly and had a 
higher death rate than control cells. Anchorage-independent 
growth, invasive and migratory traits also decreases substan-
tially in CLDN6-expressing cells, and transepithelial electrical 
resistance increases in the CLDN6-transfected cells [13]. Osa-
nai et al. [14] found that decreased expression of CLDN6 may 
increase breast tumor formation suggesting that CLDN6 may 
act as a cancer suppressor, and its downregulation may con-
tribute to the malignant progression of certain types of breast 
cancers. Conversely, increased CLDN6 expression may de-
crease breast tumor formation and contribute to the preven-
tion of breast cancer. 
In our previous studies, we found that 17β-estradiol upreg-
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Purpose: In our previous studies we showed that upregulating 
claudin-6 (CLDN6) expression may contribute to preventing 
breast cancer, and that 17β-estradiol induces a concentration- 
and time-related effect on CLDN6 mRNA and protein expression 
in MCF-7 cells. However, the mechanisms of 17β-estradiol regu-
lation of CLDN6 are still unclear. We determined the role of estro-
gen receptors in the regulation of CLDN6 expression in human 
breast cancer tissues and a cell line. Methods: CLDN6, estrogen 
receptor alpha (ERα) and estrogen receptor beta (ERβ) expres-
sion in breast cancer tissues were examined using immunohis-
tochemistry. The human breast cancer cell line, MCF-7, which 
expresses ERα but not ERβ was used. CLDN6 and ERα expres-
sion were measured by reverse transcriptase-PCR, Western 
blotting and immunofluorescent staining. Treatments with propyl 
pyrazole triol (PPT) and ICI 182, 780 (ICI) were performed. Results: 
The results revealed that CLDN6 expression was related to ERα 
in breast cancer tissues (p=0.033). PPT, an ERα-selective ligand, 
upregulated CLDN6 expression at 10
-5 mol/L after 24 hours. The 
effect of PPT on regulating CLDN6 expression in MCF-7 cells was 
blocked by ICI. Conclusion: These findings suggest that Erα re-
ulates CLDN6 expression in breast cancer tissues and that 17β- 
estradiol induces CLDN6 expression through an ERα pathway in 
MCF-7 cells.
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ulates CLDN6 expression in MCF-7 cells [15], and according 
to current reports, CLDN1, 3, and 4 expression are strongly 
related to the expression of estrogen receptors (ERs) in breast 
cancer tissues [16]. However, it is presently unclear how CLDN6 
expression is related to ERs. This study sought to determine 
the role of ERs in the regulation of CLDN6 expression. We 
examined the CLDN6, ERα and ERβ expression in breast can-
cer tissues to determine if there might be a correlation between 
CLDN6 and ERs expression. 
METHODS
Immunohistochemical analysis of CLDN6 and ERs
All invasive breast cancers used in our study were obtained 
from Jilin University. The permission for this study was granted 
by the Ethical Committee of the School of Basic Medical Sci-
ences, Jilin University. Eighty patients with surgically resected 
invasive breast carcinoma were investigated. All patients were 
women (age, 23-65 years) not undergoing any treatments. All 
samples were designated as infiltrating ductal carcinomas by 
the specialist committee of Jilin University. All tissues were 
fixed in 10% paraformaldehyde, and then paraffin-embedded 
tissues were cut into 4 μm slices, which were stained by immu-
nohistochemistry using the UltraSensitive TMS-P kit (Maxim, 
Fuzhou, China), according to the manufacturer’s instructions. 
All specimens were stained with 1:1,000 diluted anti-CLDN6 
antibody (Santa Cruz Biotechnologies, Santa Cruz, USA), anti-
ERα antibody (Bios, Beijing, China) and anti-ERβ (Bios), re-
spectively. DAB color reagent (Bios) was used. Immunostain-
ing was observed under light microscopy with 200x magnifi-
cation, and five different visual fields in each section were ex-
amined. If there was a discrepancy in staining among the five 
visual fields from the same patient, the overall staining was as-
sessed. Scoring was performed as follows: negative (-), <10% 
positive tumor cells; positive (+), ≥10% positive tumor cells. 
Cell culture and treatment
Human breast adenocarcinoma cell lines (MCF-7 and MDA-
MB-231) were cultured in Dulbecco’s modified Eagle’s medi-
um (DMEM) (GIBCO, Grand Island, USA) containing 10% 
fetal bovine serum (FBS) (BD, Tokyo, Japan), at 37°C in an at-
mosphere containing 5% CO2.
MCF-7 cells were harvested, washed twice by centrifugation 
in PBS, and then cultured in 6-well plates in DMEM contain-
ing 10% FBS for 12 hours. The culture medium was replaced 
with DMEM without FBS for 12 hours. Cells were treated for   
1 hour to 24 hours with different concentrations of propyl pyr-
azole triol (PPT) (Sigma, St. Louis, USA) (ranging from 10
-8 
mol/L to 10
-5 mol/L), 5×10
-9 mol/L 17β-estradiol (Cayman, 
Denver, USA) and 10
-7 mol/L 182780 ICI (ICI) for 24 hours. 
Control cells were cultured in DMEM only. Vacant vehicle 
control cells were cultured with DMEM including DMSO at a 
final concentration of 0.007%.
Reverse transcriptase-PCR (RT-PCR)
Total RNA was extracted from tissue using TRIzol reagent 
(Invitrogen, Carlsbad, USA). The RNeasy kit (TaKaRa, Dalian, 
China) was used according to the manufacturer’s instructions. 
RNA concentration was measured at an absorbance at 260 nm. 
Total RNA (0.5 μg) was used for reverse transcription reactions 
using M-MLV reverse transcriptase (TaKaRa) and random 
primers (TaKaRa) at 42°C for 60 minutes. One µL of the final 
mixture was used for subsequent PCR reactions using Taq 
DNA polymerase (TaKaRa). Amplification conditions were as 
follows: PCR reactions were denatured at 94°C for 2 minutes, 
followed by 28 cycles of 94°C for 30 seconds, 50-60°C for 30 
seconds, and 72°C for 1 minute. This sequence was followed 
by a final extension step of 10 minutes at 72°C. β-actin was 
used as an endogenous control. 
The PCR primers were used as follows: CLDN6, 5´-cagtcag-
ctccttcaacct-3´ (sense) and 5´-CCATCCAGAAGTGGCAGTG-3´ 
(antisense). β-actin, 5´-CCACTGCGTCGCGGGG-3´ (sense) 
and 5´-GGCAGCCAGCTCAG  CCATG-3´ (antisense). ERα, 
5´-CCTACTACCTGGAGAACGAG-3´ (sense) and 5´-CTCT- 
TCGGTCTTTTCGTATG-3´ (antisense), and ERβ, 5´-AAAA- 
GAATCATTCAATGACA-3´ (sense) and 5´-ATTAACACCT- 
CCATCCAACA-3´ (antisense) [17]. 
The reaction products were resolved on 1.5% agarose gels 
and visualized by ethidium bromide staining. The images were 
observed and photographed under an ultraviolet lamp using 
the Gel Imaging System (Bio-Rad Laboratories Inc., Hercules, 
USA). The results were analyzed by Quantity One 4.4.1 soft-
ware (Bio-Rad Laboratories Inc.).
Western blotting
Total protein was extracted using 360 µL of protein extrac-
tion fluid (Hua Te Sheng, Beijing, China) with 40 µL (10 mM) 
phenylmethanesulfonyl fluoride according to the supplier’s 
instructions. Total protein concentration was determined us-
ing a BCA Protein Assay Kit (Pierce Chemical Co., Rockford, 
USA).
For each sample, 60 μg of denatured total protein per lane 
was resolved by SDS/PAGE (15% acrylamide), and then trans-
ferred to a nitrocellulose membrane (Millipore, Billerica, USA) 
using a Semi-DRY Transfer cell (Bio-Rad Laboratories Inc.). 
The membrane was blocked with 5% defatted milk (in 25 mM 
Tris, pH 8.0, 125 mM NaCl, 0.1% Tween 20) for 1 hour at 
room temperature and then incubated with 1:1,000 diluted 22   Liu Yafang, et al.
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anti-CLDN6 (Santa Cruz Biotechnologies) or anti- ERα (Santa 
Cruz Biotechnologies) antibody at 4°C overnight. After wash-
ing three times with PBS, the membrane was incubated with a 
horseradish peroxidase conjugated anti-goat IgG or anti-rab-
bit IgG (1:1,000; Santa Cruz Biotechnologies) secondary anti-
body at room temperature for 1 hour. After washing, the im-
munoreactive bands were visualized using an ECL Western 
blotting system (GE, Buckinghamshire, UK) and exposed to 
X-ray film (Eastman Kodak, Xiamen, China). Anti-β-actin 
(Santa Cruz Biotechnologies) antibody was used as the endog-
enous control. 
Immunofluorescence staining
MCF-7 cells were seeded onto small coverslips and treated 
with 5×10
-9 mol/L 17β-estradiol (Cayman, Denver, USA), 10
-5 
mol/LPPT and 10
-7 mol/L ICI for 24 hours. After washing three 
times with PBS, the cells were fixed with 4% paraformalde-
hyde for 30 minutes at room temperature. The cells were in-
cubated with 0.3% H2O2 and 30 µL goat serum for 30 minutes, 
respectively. The cells were stained with 1:500 diluted anti-
CLDN6 antibodies (Santa Cruz Biotechnologies) at 4ºC over-
night, and 1:50 diluted rhodamine (red)-conjugated anti-goat 
IgG was used as a secondary antibody. The cells were photo-
graphed under a confocal microscope (Olympus, Tokyo, Japan).
Statistical analysis
All data were analyzed with SPSS statistics software (version 
13.0; SPSS Inc., Chicago, USA). Relationships between CLDN6 
and ERs were assessed by the Pearson’s chi-square test. The 
relative amount of the target mRNA or protein expression was 
calculated by the ratio of the integrated optical density (IOD) 
of the target mRNA or target protein to the IOD of the house-
keeping gene or protein β-actin. The data are presented as 
means±standard errors (SE) and evaluated using indepen-
dent t-tests. A p-value <0.05 was considered statistically sig-
nificant.
RESULTS
Correlation between expression of CLDN6 and ERs
CLDN6 and ERs expression were examined in 80 breast 
cancer tissues by immunohistochemical analysis to determine 
whether CLDN6 expression was regulated by estrogen in hu-
man breast cancers. All breast cancer tissue sections were 
stained with specific antibodies to CLDN6, ERα and ERβ, re-
spectively. ERα was located at cell nuclei (Figure 1), and CLDN6 
was located on cell membranes (Figure 2). ERβ was located at 
cell nuclei and cytoplasm (data not shown).
Figure 1. Estrogen receptor-α (ERα) expression in breast carcinoma, as 
detected by immunohistochemistry. Staining was specific for tumor tis-
sue, and nuclear staining was observed. Bar=20 µm. (A) Negative ex-
pression of ERα in a breast carcinoma. (B) Positive expression of ERα in 
a breast carcinoma.
A B
Figure 2. Claudin-6 (CLDN6) expression in a breast carcinoma, as de-
tected by immunohistochemistry. Staining was specific for tumor tissue, 
and membrane staining was observed. Bar=20 µm. (A) Negative 
CLDN6 expression in a breast carcinoma. (B) Positive CLDN6 expres-
sion in a breast carcinoma.
A B
Table 1. Correlation between CLDN6 protein and ERα protein in breast 
cancers
ERα
p-value
- +
CLDN6
   - 22 25 0.033
   +   8 25
The expression of claudin-6 (CLDN6) and estrogen receptor-α (ERα) was de-
termined by immunohistochemistry, and the correlation between CLDN6 and 
ERα was determined by the Pearson’s chi-square test. 
Table 2. Correlation between CLDN6 protein and ERβ protein in breast 
cancers
ERβ
p-value
- +
CLDN6
   - 18 29 0.552
   + 13 20
The expression of claudin-6 (CLDN6) and estrogen receptor-β (ERβ) was de-
termined by immunohistochemistry, and the correlation between CLDN6 and 
ERβ was determined by the Pearson’s chi-square test. Estrogen Receptor α Upregulates CLDN6 Expression 23
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Figure 3. Estrogen receptor-α (ERα) and estrogen receptor-β (ERβ) expression in MCF-7 cells, determined by RT-PCR (A) and Western blot assay (B). 
MCF-cells, different with MDA MB 231 cells, only expressed ERα, but not ERβ. 
Figure 4. MCF-7 cells were treated with different concentrations of propyl pyrazole triol (PPT) for 1 to 24 hr. PPT induced estrogen receptor-α (ERα) 
and claudin-6 (CLDN6) expression in a concentration- and time-dependent manner. (A) RT-PCR was used to determine ERα and CLDN6 expression 
in MCF-7 cells treated with different concentrations of PPT for 24 hr. The results showed that 10
-6 mol/L and 10
-5 mol/L PPT had the greatest effect 
on inducing ERα expression but only 10
-5 mol/L PPT induced CLDN6 expression. (B) The Western blot assay was performed to detect ERα and 
CLDN6 protein expression in MCF-7 cells treated with different concentrations of PPT for 24 hr. The changes in protein levels were coincident with 
mRNA levels. (C) CLDN6 expression in MCF-7 cells treated with 10
-5 mol/L PPT for 1 to 24 hr. The results showed that 10
-5 mol/L PPT for 24 hr had 
the greatest effect on inducing ERα and CLDN6 mRNA expression levels. (D) The Western blot assay confirmed that protein levels were associated 
with mRNA levels.
*p<0.05, vs. MCF-7 cells (statistically significant).
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Fifty tumors were stained positive for ERα, and 30 tumors 
were negative (Table 1). Half (25/50) of the 50 ERα-positive 
tumors were stained positively for CLDN6, but only 27% (8/ 
30) of the ERα-negative tumors stained positively for CLDN6. 
The correlation was found between CLDN6 and ERα (p= 
0.033). However, 40.8% (20/49) of the ERβ-positive tumors 
stained positively for CLDN6, and 41.9% (13/31) of the ERβ-
negative tumors stained positively for CLDN6. No correlation 
was found between CLDN6 and ERβ (p=0.552) (Table 2).
Expression of ERα and ERβ in MCF-7 cells
In our previous works, we found that 17β-estradiol induces 
CLDN6 mRNA and protein expression in MCF-7 cells and that 
the effects of 17β-estradiol could be blocked by a selective estro-
gen receptor antagonist, ICI [15]. ERα and ERβ expression was 
examined in MCF-7 cells to determine with ER subset was in-
volved in the process of 17β-estradiol regulated CLND6 expres-
sion. As s result, MCF-7 cells expressed ERα, but not ERβ (Figure 
3). MDA-MB-231 cells were used as an ERβ positive control.
PPT induced CLDN6 expression in MCF-7 cells with 
concentration and time dependence
To elucidate the contribution of ERα in the regulation of 
CLDN6 expression, MCF-7 cells were treated with different 
concentrations of PPT, a selective ERα agonist (from 10
-8 mol/
L to 10
-5 mol/L), for 1 to 24 hours. ERα and CLDN6 expression 
were examined using RT-PCR and Western blotting. We found 
that 10
-5 mol/L and 10
-6 mol/L PPT could profoundly upregu-
lates ERα expression, but only 10
-5 mol/L PPT induced the ex-
pression of CLDN6 mRNA and protein levels after 24 hours 
(Figure 4).
Effect of ER antagonist on PPT-induced CLDN6 expression
To confirm that CLDN6 expression was regulated by PPT 
through ERα pathway, MCF-7 cells were treated with ICI, a 
selective estrogen receptors antagonist, coincident with PPT 
treatment. CLDN6 mRNA expression was detected using RT-
PCR. ICI significantly blocked PPT-induced CLDN6 mRNA 
expression (Figure 5A). CLDN6 protein expression was de-
tected using Western blotting. The results confirmed that 17β- 
estradiol and PPT induced CLDN6 protein expression, and 
that ICI could block the effect (Figure 5B). Immunofluores-
cent staining showed that 17β-estradiol and PPT induced 
CLDN6 expression which was located at cell membranes 
(Figure 5C).
Figure 5. Effect of ICI182780 (ICI) on propyl pyrazole triol (PPT)-induced claudin-6 (CLDN6) expression. (A) The effect of ICI on PPT-induced CLDN6 
mRNA expression was determined by RT-PCR. Lane 1 and Lane 2 showed the expression of CLDN6 in control cells (C) and vacant vehicle control 
cells (VE) respectively. Lanes 3-5 showed that 5×10
-9 mol/L 17β-estradiol (E2) and 10
-5 mol/L PPT for 24 hr induced CLDN6 expression respectively 
or collectively. Lane 6 shows that ICI significantly blocked the effect of PPT. (B) The Western blot assay revealed CLDN6 protein expression in the six 
groups. Lanes 3-5 showed that CLDN6 protein expression was significantly upregulated in MCF-7 cells treated with 17-β-estradiol or (and) PPT for 24 
hr. Lane 6 shows that the effect of PPT could be blocked by ICI. (C) Immunofluoresce staining showed CLDN6 expression on the membranes of MCF-
7 cells treated with 17β-estradiol or (and) PPT for 24 hr.  
*p<0.05, vs. MCF-7 cells (statistically significant).
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DISCUSSION
Infiltrating ductal carcinomas of the breast are believed to 
arise from the terminal mammary duct. During the process of 
tumorigenesis and development, mammary epithelial cells ac-
quire mesenchymal characteristics (epithelial/mesenchyme 
transition, EMT), with altered cell polarity and adhesion, which 
contributes to the dissemination of tumor cells through blood 
vessels and lymphatics from the original site [18]. Current re-
ports suggest that tight junction protein expression or locations 
of specific tight junction-associated expression are altered be-
fore the initiation of EMT [19].
Tight junctions are located at the extreme apical region of 
the junction complex in epithelial and endothelial cells, where 
they can seal intracellular gaps, maintain cell polarity, adhe-
sion, and permeability as well as regulate cell proliferation and 
differentiation [1,2]. 
Tight junctions mainly consist of CLDNs, occludin, junc-
tional adhesion molecules. However, CLDNs are major con-
stituents and determine the barrier properties of tight junc-
tions [18]. CLDN6, one of 24 members of the CLDN family, 
was first identified by searching for sequences in genomic data- 
bases [5]. CLDN6 is similar to CLDN1, 7, 8, 10, 14, 15, 17, and 
19 [20], as it four transmembrane domains, and two extracel-
lular loops [21]. CLDN6 is located on chromosome 16 p13.3 
and encodes a 23 kDa membrane protein of 219 amino acids 
[5]. Recent reports show that CLDN6 plays important roles in 
cells under both physiological and pathological conditions. For 
example, CLDN6 can regulate adipogenesis and fat deposition 
[22], it is required for normal blastocyst formation [23], and 
its expression occurs in early development, with particular at-
tention to definitive endoderm derivatives [24]. CLDN6 is ex-
pressed very early in epidermal morphogenesis [1], and it is 
important for maintaining permeability barriers and transepi-
thelial resistance in epidermal cells [11]. 
The current study herein has shown that CLDN6 was si-
lenced in esophageal squamous cell carcinoma [25]. In our pre-
vious work, we have identified CLDN6 as a potential mam-
mary cancer suppressor gene, which may contribute to the 
mammary cancer resistant phenotype observed in Copenha-
gen rats, and CLDN6 expression was undetectable or at low 
levels in human and rat mammary cancer cell lines [12].
In addition, we demonstrated that MCF-7 cells transfected 
with CLDN6 grow slower, show an increased rate of cell death, 
have reduced 2-D and 3-D colony-forming ability, and de-
creased invasiveness and cell migration [13]. These results sug-
gest that CLDN6 could have beneficial effects for inhibiting 
carcinogenesis and the malignant progression of certain types 
of breast cancers. Our further studies found that 17β-estradiol 
upregulates CLDN6 mRNA and protein expression in MCF-7 
cells [15]. However, the regulatory mechanisms involved in the 
process of 17β-estradiol induced CLDN6 expression are not 
fully understood. 
A significant association exists between CLDN1, 3, and 4, and 
ERs in breast cancers [16]. However, to our knowledge, no in-
formation is available about CLDN6. So, we examined CLDN6 
and ERs expression in the tissues of 80 patients with breast can-
cers using immunohistochemistry, where the results showed a 
significant association between CLDN6 and ERα expression. 
In 50 ERα-positive tumors, 25 (50%) stained positive for CLDN6, 
but only eight of 30 ERα-negative tumors (27%) were positive 
for CLDN6 (Table 1). But no significant association was ob-
served between CLDN6 and ERβ expression (Table 2). Previ-
ous reports have shown that ERα-negative tumors represent a 
more invasive phenotype and a poorer prognosis compared with 
ERα-positive breast cancers [26]. The decreased expression of 
CLDN6 protein in the ERα-negative breast cancers was coinci-
dent with our hypothesis that CLDN6 acts as an anti-oncogene, 
and its expression might be regulated by estrogen via ERα.
A recent report shows that 17β-estradiol has biphasic effects 
on occludin expression [17]. In our previous study, we found 
that 17β-estradiol significantly upregulated CLDN6 expres-
sion with a maximal effect at 5×10
-9 mol/L for 24 hours and 
that the effect of 17β-estradiol could be blocked by the ERs an-
tagonist ICI [15]. To investigate which ER subset was involved 
in the process of 17β-estradiol induced CLDN6 expression, we 
examined the expression of ERs in MCF-7 cells. Similar to an 
earlier report, MCF-7 cells expressed ERα, but not ERβ (Figure 
3) [17]. The ERα agonist PPT and the ERs antagonist ICI were 
employed in the present study, and the results revealed that 
CLDN6 mRNA and protein expression could be induced by 
PPT (Figure 4), and that the induction could be blocked by ICI 
(Figure 5). We detected the location of CLDN6 protein in MCF-
7 cells using immunofluorescent staining, but only the MCF-7 
cells treated with 17β-estradiol or (and) PPT showed CLDN6 
expression located at the plasma membranes (Figure 5C).
Estrogen has a wide array of cell and tissue-specific effects. 
The biological effects of estrogen are mediated by ERα and 
ERβ [27], which are members of a large superfamily of nuclear 
receptors regulating the expression of target genes via two path-
ways. The first is a genomic pathway, and the second is non- 
genomic pathway The latter is mediated by membrane-associ-
ated ERs and occurs so rapidly that the effects of estrogen do 
not depend on RNA and protein synthesis activation [28]. In 
the classical genomic pathway, estrogen binds to nuclear re-
ceptors, the receptors dimerize and bind to specific response 
elements known as estrogen response elements (EREs) locat-
ed in target gene promoter [28]. However, a number of studies 26   Liu Yafang, et al.
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have shown that ERs can regulate the expression of several 
genes without binding directly to DNA, but through modulat-
ing the function of other transcription factors by protein-pro-
tein interactions in the nucleus [29]. The interaction of ERs 
with the activator protein 1 (AP-1) transcription factor com-
plex is an example of such an ERE-independent genomic ac-
tions [30]. This mode of activation regulates the expression of 
specific downstream genes and may require hours to days in a 
single cell type [29]. According to our previous works, 17β- 
estradiol could upregulate CLDN6 mRNA and protein ex-
pression in MCF-7 cells after 24 hours [15]. In this study, PPT 
induced CLDN6 mRNA and protein expression at 24 hours 
(Figure 4), indicating that estrogen could modify the expres-
sion of CLDN6 mRNA and protein through a genomic path-
way mediated by ERα.
Our study provides the first direct evidence that CLDN6 
expression is associated with ERα in breast cancer tissues, and 
that PPT could induces CLDN6 mRNA and protein expres-
sion in MCF-7 cells. A further study showed that this effect 
could be blocked by the ER antagonist, ICI. We concluded that 
estrogen could induce CLDN6 expression via an ERα path-
way in breast cancer tissues and MCF-7 cells. 
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